Status:
COMPLETED
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
20+ years
Phase:
PHASE3
Brief Summary
To verify the non-inferiority of exemestane compared to anastrozole in time to tumor progression (TTP), the primary efficacy endpoint, in postmenopausal women with advanced/recurrent breast cancer.
Eligibility Criteria
Inclusion
- Have histologically or cytologically confirmed breast cancer at original diagnosis. At study entry, the patient must have metastatic progressive or locally recurrent inoperable breast cancer.
Exclusion
- Having received any hormonal therapy (e.g., Tamoxifen, LHRH-agonists) ovariectomy or any chemotherapy for advanced/recurrent breast cancer
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
298 Patients enrolled
Trial Details
Trial ID
NCT00143390
Start Date
April 1 2005
End Date
December 1 2010
Last Update
January 25 2012
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Toyohashi, Aiche, Japan
2
Pfizer Investigational Site
Anjo, Aichi-ken, Japan
3
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
4
Pfizer Investigational Site
Toyoake, Aichi-ken, Japan